Acute myeloid leukemia, FLT3 internal tandem duplication
MONDO:0100415Any acute myeloid leukemia that has the chromosomal anomaly FLT3 internal tandem duplication. (A genetic abnormality that arises from duplications of the juxtamembrane portion of the gene and results in constitutive activation of the FLT3 receptor tyrosine kinase protein in early hematopoietic progenitor cells. It is associated with acute myelogenous leukemia where it appears to correlate with a poor prognosis.)
Also known as: AML, Activating FLT3-ITD Gene Mutation, AML, Activating FLT3-ITD Mutation, AML, FLT3 ITD, AML, FLT3 internal tandem duplication, AML, FLT3-ITD, AML, FLT3-ITD Activating Mutation, AML, FLT3-ITD Mutation, AML, FLT3/ITD Mutation
3109 clinical trials for this condition and its sub-types, 18 tagged with Acute myeloid leukemia, FLT3 internal tandem duplication itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope for AML patients: quizartinib maintenance trial launches
Disease control Recruiting nowThis study tests two different doses of the drug quizartinib as a maintenance therapy for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission after initial treatment and have not had a stem cell transplant. The goal …
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo targets resistant leukemia
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs, gilteritinib and momelotinib, for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe dose of momelotinib when given with gilteritini…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Cure leukemia
Disease control Recruiting nowThis early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drugs work by blocking different signals that …
Phase 1 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug gilteritinib may beat standard therapy in preventing AML relapse after transplant
Disease control Recruiting nowThis Phase 3 trial tests whether the drug gilteritinib is better than sorafenib at keeping leukemia from coming back in patients with a specific gene mutation (FLT3-ITD) after a stem cell transplant. About 594 adults and teens will take one of the two pills daily for up to 2 year…
Phase 3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
New drug cocktail may replace bone marrow transplant for some leukemia patients
Disease control Recruiting nowThis study tests a new treatment for adults with a specific type of acute myeloid leukemia (FLT3-ITD AML). The goal is to see if a combination of targeted drugs (gilteritinib, venetoclax, azacitidine) followed by high-dose chemotherapy can control the disease well enough to avoid…
Phase 2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo tackles Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage study tests a combination of two drugs, vyxeos and gilteritinib, for adults whose FLT3-mutated acute myeloid leukemia has come back or not responded to prior treatment. The goal is to find the safest dose and see how many patients achieve remission. Participants …
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New leukemia drug candidate undergoes heart safety check
Knowledge-focused Recruiting nowThis early-stage trial is testing whether a single dose of XY0206 tablets affects the heart's electrical activity (QTc interval) in 45 healthy Chinese adults. Participants are randomly assigned to receive XY0206, a placebo, or an active control (moxifloxacin). The study lasts 3 d…
Phase 1 • Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:01 UTC